Page 113 - Škrgat, Sabina, ed. 2022. Severe Asthma - Basic and Clinical Views. Koper: University of Primorska Press. Severe Asthma Forum, 1
P. 113
(Sheff). 2021 Mar;17(1):200324. doi: agement of patients with severe asth- 113
10.1183/20734735.0324-2020. ma. Clin Transl Allergy. 2020 Nov
23. Brusselle GG, Koppelman GH. Biolog- 6;10(1):46. doi: 10.1186/s13601-020- t2-low asthma
ic Therapies for Severe Asthma. N Engl 00353-8.
J Med. 2022 Jan 13;386(2):157-71. 32. Katsube O, Kono Y, Tsuzuki R, et al.
24. Casale TB, Bateman ED, Vandewalker An exacerbation of severe asthma with
M, et al. Tiotropium Respimat Add-on fungal sensitization successfully treat-
Is Efficacious in Symptomatic Asthma, ed with voriconazole via a reduction of
Independent of T2 Phenotype. J Al- the fungal burden. Allergol Int. 2019
lergy Clin Immunol Pract. 2018 May- Oct;68(4):549-51.
Jun;6(3):923-35.e9. 33. Tiotiu A, Salvator H, Jaussaud R, et al.
25. Svenningsen S, Nair P. Asthma En- Efficacy of immunoglobulin replace-
dotypes and an Overview of Targeted ment therapy and azithromycin in se-
Therapy for Asthma. Front Med (Laus- vere asthma with antibody deficiency.
anne). 2017 Sep 26;4:158. doi: 10.3389/ Allergol Int. 2020 Apr;69(2):215-22.
fmed.2017.00158. 34. Pepper AN, Renz H, Casale TB, et al.
26. Gibson PG, Yang IA, Upham JW, Biologic Therapy and Novel Molec-
et al. Efficacy of azithromycin in se- ular Targets of Severe Asthma. J Al-
vere asthma from the AMAZES lergy Clin Immunol Pract. 2017 Jul-
randomised trial. ERJ Open Res. Aug;5(4):909-16.
2019 Dec 23;5(4):00056-2019. doi: 35. Siddiqui S, Denlinger LC, Fowler SJ,
10.1183/23120541.00056-2019. et al. Unmet Needs in Severe Asthma
27. Sasaki F, Yokomizo T. The leukotriene Subtyping and Precision Medicine Tri-
receptors as therapeutic targets of in- als. Bridging Clinical and Patient Per-
flammatory diseases. Int Immunol. spectives. Am J Respir Crit Care Med.
September 2019;31(9):607–15. 2019 Apr 1;199(7):823-9.
28. Davino-Chiovatto JE, Oliveira-Jun- 36. Patel GB, Peters AT. Comorbidities as-
ior MC, MacKenzie B, et al. Mon- sociated with severe asthma. J Precis
telukast, Leukotriene Inhibitor, Reduc- Respir Med. 2019 Dec;2(1):5-9.
es LPS-Induced Acute Lung Inflamma-
tion and Human Neutrophil Activation.
Arch Bronconeumol (Engl Ed). 2019
Nov;55(11):573-80.
29. Culpitt SV, de Matos C, Russell RE,
et al. Effect of theophylline on in-
duced sputum inflammatory indices
and neutrophil chemotaxis in chron-
ic obstructive pulmonary disease. Am
J Respir Crit Care Med. 2002 May
15;165(10):1371-6.
30. Kawamatawong T. Phosphodiester-
ase-4 Inhibitors for Non-COPD Res-
piratory Diseases. Front Pharmacol.
2021 Aug 5;12:518345. doi: 10.3389/
fphar.2021.518345.
31. Rapeport WG, Ito K, Denning DW.
The role of antifungals in the man-
10.1183/20734735.0324-2020. ma. Clin Transl Allergy. 2020 Nov
23. Brusselle GG, Koppelman GH. Biolog- 6;10(1):46. doi: 10.1186/s13601-020- t2-low asthma
ic Therapies for Severe Asthma. N Engl 00353-8.
J Med. 2022 Jan 13;386(2):157-71. 32. Katsube O, Kono Y, Tsuzuki R, et al.
24. Casale TB, Bateman ED, Vandewalker An exacerbation of severe asthma with
M, et al. Tiotropium Respimat Add-on fungal sensitization successfully treat-
Is Efficacious in Symptomatic Asthma, ed with voriconazole via a reduction of
Independent of T2 Phenotype. J Al- the fungal burden. Allergol Int. 2019
lergy Clin Immunol Pract. 2018 May- Oct;68(4):549-51.
Jun;6(3):923-35.e9. 33. Tiotiu A, Salvator H, Jaussaud R, et al.
25. Svenningsen S, Nair P. Asthma En- Efficacy of immunoglobulin replace-
dotypes and an Overview of Targeted ment therapy and azithromycin in se-
Therapy for Asthma. Front Med (Laus- vere asthma with antibody deficiency.
anne). 2017 Sep 26;4:158. doi: 10.3389/ Allergol Int. 2020 Apr;69(2):215-22.
fmed.2017.00158. 34. Pepper AN, Renz H, Casale TB, et al.
26. Gibson PG, Yang IA, Upham JW, Biologic Therapy and Novel Molec-
et al. Efficacy of azithromycin in se- ular Targets of Severe Asthma. J Al-
vere asthma from the AMAZES lergy Clin Immunol Pract. 2017 Jul-
randomised trial. ERJ Open Res. Aug;5(4):909-16.
2019 Dec 23;5(4):00056-2019. doi: 35. Siddiqui S, Denlinger LC, Fowler SJ,
10.1183/23120541.00056-2019. et al. Unmet Needs in Severe Asthma
27. Sasaki F, Yokomizo T. The leukotriene Subtyping and Precision Medicine Tri-
receptors as therapeutic targets of in- als. Bridging Clinical and Patient Per-
flammatory diseases. Int Immunol. spectives. Am J Respir Crit Care Med.
September 2019;31(9):607–15. 2019 Apr 1;199(7):823-9.
28. Davino-Chiovatto JE, Oliveira-Jun- 36. Patel GB, Peters AT. Comorbidities as-
ior MC, MacKenzie B, et al. Mon- sociated with severe asthma. J Precis
telukast, Leukotriene Inhibitor, Reduc- Respir Med. 2019 Dec;2(1):5-9.
es LPS-Induced Acute Lung Inflamma-
tion and Human Neutrophil Activation.
Arch Bronconeumol (Engl Ed). 2019
Nov;55(11):573-80.
29. Culpitt SV, de Matos C, Russell RE,
et al. Effect of theophylline on in-
duced sputum inflammatory indices
and neutrophil chemotaxis in chron-
ic obstructive pulmonary disease. Am
J Respir Crit Care Med. 2002 May
15;165(10):1371-6.
30. Kawamatawong T. Phosphodiester-
ase-4 Inhibitors for Non-COPD Res-
piratory Diseases. Front Pharmacol.
2021 Aug 5;12:518345. doi: 10.3389/
fphar.2021.518345.
31. Rapeport WG, Ito K, Denning DW.
The role of antifungals in the man-
